Quick Facts


Cerianna (fluoroestradiol F 18) is the first FDA-approved F-18 PET imaging agent specifically indicated for use in patients with recurrent or metastatic breast cancer. With a new product launch on the horizon, Zionexa USA needed a partner to develop its digital presence and educate the market.


jscTEK developed a custom, fully responsive website for Ceriana that focused on ease of use, branding and physician education. We created the site to allow physicians to receive on demand training via a portal that leverages an NPI authorization API for verification purposes. Integrated with tracking metrics to monitor and improve site conversions and performance as they grow, the site is also fully compliance with FDA guidelines.


As a result, Cerianna has quickly educated the market audience of physicians and will be commercially available beginning in late 2020/early 2021.

Let's make something great together

Ready to optimize your marketing and see better results?